Carlsmed initiated with a Buy at Truist

Truist initiated coverage of Carlsmed (CARL) with a Buy rating and $18 price target The firm views Carlsmed as a high growth spine implant company with more predictable alignment and reduced revision rates. The company’s Aprevo is the first U.S. approved personalized spine implant utilizing an artificial intelligence algorithm to address traditional implant limitations, the analyst tells investors in a research note.